key: cord-1042656-blongyrr
authors: Jaiswal, Sarita Rani; Malhotra, Pankaj; Mitra, Dipendra K; Chakrabarti, Suparno
title: Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure
date: 2020-07-01
journal: Mediterr J Hematol Infect Dis
DOI: 10.4084/mjhid.2020.047
sha: f13a9206a6f85779b7d8b2ff108cd74daed140d0
doc_id: 1042656
cord_uid: blongyrr

nan

Introduction. The current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) manifesting as severe pneumonia in a subgroup of patients 1,2 has generated interest in the immunological response to this virus or the lack of it. 3 Despite being a novel virus, many of the patients are either asymptomatic or mildly symptomatic. 4 On the other hand, a subgroup of patients demonstrates a severe cytokine storm, similar to that witnessed in the macrophage activation syndrome (MAS) or hemophagocytic syndrome (HPS). 5 This response begs the question if there exists innate protection against this new pathogen and, if so, what that might be.

Cells and Cytomegalovirus. Natural Killer (NK) cells are the frontline warriors in the launch of antiviral immunity. However, these cells act in an antigenindependent manner and last for a short while, a characteristic of the innate immune response. In mice, it was observed that NK cells bearing Ly49H receptors were preferentially expanded in response to cytomegalovirus (CMV) infection, the viral protein m157 being the trigger. 6 More importantly, these cells persisted and expanded in response to re-challenge with the virus, mimicking a memory response akin to the adaptive immune counterpart. A similar subtype was identified in humans with the expansion of NK cells expressing a C lectin type receptor NKG2C, when cultured with CMV infected fibroblasts. 7 This subtype was further characterized by the absence of the corresponding inhibitory receptor NKG2A, a high expression of CD57 receptor (a marker of maturation), an amplified antibody-dependent cellular cytotoxicity through the CD16 receptor and a strong interferongamma (IFNγ) response. While conventional effector NK cells are short-lasting, these cells were found to last for years in CMV seropositive individuals, but not in those who are CMV naïve. 8 Thus, the NKG2C subset of NK cells was identified as a unique subgroup of innate cells with a memory phenotype generated by CMV infection. However, these cells were found to expand in response against several RNA viruses as well.

Hypothesis. Our group has been working on this memory subset of NK cells following haploidentical hematopoietic cell transplantation (HCT) with a novel approach of T cell costimulation blockade with CTLA4Ig. High NKG2C+ NK cell levels were observed to be protective against the recurrence of CMV reactivation, as well as reactivation of adenovirus in this protocol. 9, 10 In addition, NKG2C+ NK cells inversely correlated with graft-versus-host disease (GVHD) following haploidentical HCT in our study, 11 confirming similar findings reported by others as well. 12 This has led us to speculate whether these cells may be protective against the SARS-CoV-2 infection as well. If so, the possibility of these cells being isolated and expanded from haploidentical family donors and used for adoptive immunotherapy against COVID-19 is worth consideration. The following sections discuss the rationale for this proposition and its possible implications.

This subset of NK cells with NKG2C expression has also been found to rapidly expand following influenza vaccination with increased IFNγ release. 13 Prolonged memory response to influenza strains is uncommon and annual vaccination is recommended. In a subgroup of 21 HCT recipients prospectively evaluated by us during a seasonal outbreak in 2019, 8 developed H1N1 infection. 14 All eight patients had high NKG2C+NK cell levels (22.1 ± 9.5%), with a substantial increase in these cells four weeks following the infection (41.8 ± 13.3%). All patients had mild to moderate symptoms with none developing lower respiratory infections, suggesting a possible role of expanded NKG2C+NK cells in retarding the progression of H1N1 infection. A similar expansion of NKG2C+NK cells has been reported following Hantavirus infections, who were CMV seropositive. 15 This subset of NK cells was also associated with a lower viral load in those with HIV infections. 16 These observations suggest that while CMV infection is essential for the development of the NKG2C subset of the NK cell population, this population may also functionally expand in response to a wide array of viruses. The response against both DNA and RNA viruses in an antigen-independent manner, in terms of further expansion, sets these NK cells apart from memory cells of adaptive lineage, which are highly antigen-specific in their response. 17 A similar memory response of NK cells has been demonstrated against mycobacterium in mouse models. 18 In patients with latent infection with mycobacterium tuberculosis, vaccination with Bacillus Calmette-Guérin (BCG) induced a long term NK cell response lasting for 12 months. 19 Can NKG2C+NK Cells Provide Protective Immunity Against COVID-19? Studies on immunological predispositions and their consequences, concerning coronavirus disease 2019 (COVID-19), are still scant. However, a study from China has shown an increase in the expression of NKG2A receptors in NK cells following SARS-CoV-2 infection and a corresponding decrease in this inhibitory receptor following recovery. 20 Even though the report does not allude to the NKG2C+ NK cell subset, it is worth noting that the expression of NKG2A inversely correlated with NKG2C, as shown by our group and also by others. 21 HLA E is a ligand for both NKG2A as well as NKG2C receptors, with the former binding its ligand with a higher affinity. 22 Thus, the absence of NKG2A expression is a pre-requisite for the binding of NKG2C to the putative receptors and further cytotoxicity. Virus infections often upregulate HLA-E expression on the infected cells, preventing its killing by NK cells expressing NKG2A, despite having the full repertoire of cytotoxic receptors. 23 Thus, a higher proportion of NKG2A-NKG2C+NK cells might offer better protection against such infections. In addition, the correlation between high expression of NKG2A and an adverse outcome in those with COVID-19 has prompted researchers to speculate if monoclonal antibodies against NKG2A such as Monalizumab may potentially reverse the inhibition of the innate immune system induced by the virus. 24, 25 Furthermore, in-vitro studies have shown that signaling via specific Notch ligands in cord progenitor cells, such as Jagged2, Delta1, or Delta4, may result in the expansion of an immature phenotype of NK cells without NKG2A expression. 26 These NKG2A-KIR-CD56bright NK cells were shown to upregulate receptors such as NKp44, NKp30, and DNAM-1. This does not conform to the natural stages of maturation of NK cells in-vivo and rather reflects an accelerated functional ability despite an immature phenotype, characterized by augmented release of IFNγ and cytotoxicity against the K562 cell line-a functional phenotype resembling NKG2A-NKG2C+ NK cells. If developed clinically, this might represent a novel way of harnessing functional NK cells from cord blood, enabling the genesis of an off the shelf product for antiviral as well as anticancer immunotherapy.

Harnessing Antigen-Independent Properties of Innate Memory Cells in COVID-19. In the earlier widespread coronavirus infections as in SARS-CoV-1, a lack of cytotoxic NK cells was strongly correlated with the severity of the disease. 27 This has drawn attention to the possible use of NK cell-based immunotherapy in COVID-19. Derived from the above findings, we hypothesize that this unique group of innate immune cells may have a specific protective role in COVID-19. Given the large number of patients infected with this virus across the globe, a study of the role of NKG2C+NK cells becomes both pertinent and urgent, as these cells may be boosted by influenza vaccination as well as BCG [28] [29] [30] and can be generated ex-vivo for adoptive immunotherapy from CMV seropositive donors, as prior CMV infection is a prerequisite for the generation and expansion of this unique population of NK cells with a memory phenotype. 31 Furthermore, the fatal HPS often found in fatal cases of COVID-19, 5 is an end-result of abortive NK cell cytotoxicity, lending further credence to the hypothesis that cytotoxic NK cells and the NKG2C subset, in particular, may protect against severe disease in patients infected with COVID-19. Our early results on the use of heat-killed Mycobacterium w (Mw) in patients diagnosed with Covid-19 infection are encouraging. 32 If that be the case, an early immunological intervention might reduce disease severity as well as mortality. We have proposed a similar study to evaluate the NK cell subsets in those exposed to SARS-CoV2 and those developing the disease in India as CMV seropositivity is ubiquitous in the population. 33 The fact that NKG2A-NKG2C+ NK cells have been found to be protective against GVHD in haploidentical HCT, despite having a potent antiviral and antitumor activity, is encouraging. 11, 12 If found to be protective, this may indicate an opportunity to intervene and boost this subset through either vaccination or adoptive immunotherapy from family donors.

A Novel Coronavirus from Patients with Pneumonia in China

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical and immunologic features in severe and moderate Coronavirus Disease

Characteristics of COVID-19 infection in Beijing

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Adaptive immune features of natural killer cells

Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

CTLA4Ig-based T-cell costimulation blockade is associated with reduction of adenovirus viremia following posttransplantation cyclophosphamide-based haploidentical transplantation

Early Expansion of CD56dimNKG2Alow with Late Surge and Persistence of CD56dimNKG2AnegNKG2Cbright NK Cells Attenuate Cytomegalovirus (CMV) Replication and Recurrence As Well As Leukemia Relapse Following Haploidentical HSCT with T Cell Costimulation Blockade and PTCy

Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease

The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease

Influenza Vaccination Generates Cytokine-Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection

Prophylactic Oseltamivir During Major Seasonal Influenza H1N1 Outbreak Might Reduce Both H1N1 And Associated Pulmonary Aspergillosis In Children Undergoing Haploidentical Transplantation

Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus

NKG2C(+) memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147

Memory responses of natural killer cells

IL-21-dependent expansion of memory-like NK cells enhances protective immune responses against Mycobacterium tuberculosis. Mucosal www.mjhid.org

Bacillus Calmette-Guerin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Alterations In NKG2A and NKG2C Subsets Of Natural Killer Cells following Epstein Barr Virus Reactivation In CTLA4Ig Based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease

Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E

HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells

Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents

NKG2A and COVID-19: another brick in the wall

The Notch Ligands Jagged2, Delta1, and Delta4 Induce Differentiation and Expansion of Functional Human NK Cells from CD34+ Cord Blood Hematopoietic Progenitor Cells

The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome

Influenza vaccine induces intracellular immune memory of human NK cells

Vaccinating for natural killer cell effector functions

BCGinduced trained immunity in NK cells: Role for non-specific protection to infection

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

Safety of an immunomodulator Mycobacterium W in COVID-19

Cytomegalovirus infection: An Indian perspective